Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | POLA1 | P09884 | 1/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7039861 | 0.84 | SLC29A1 (0.40) | ADORA2APOLBSLC29A1 | |
| SCHEMBL7031391 | 0.82 | RNASE1 (0.52) | RNASE1 | |
| SCHEMBL7031388 | 0.82 | RNASE1 (0.52) | RNASE1 | |
| SCHEMBL7105462 | 0.80 | POLB (0.56) | KDM4EALDH1A1MEN1KMT2ARNASE1 | |
| SCHEMBL21828787 | 0.77 | KDM4E (0.71) | KDM4EPOLA1TAS1R3TAS1R1ADORA1 | |
| SCHEMBL19666768 | 0.77 | KDM4E (0.71) | KDM4EPOLA1TAS1R3TAS1R1ADORA1 | |
| SCHEMBL7031559 | 0.77 | SLC29A1 (0.34) | MEN1KMT2AMAPTSLC29A1ADORA3 | |
| SCHEMBL10067865 | 0.77 | KDM4E (0.63) | KDM4EPOLA1TAS1R3TAS1R1ADORA1 | |
| SCHEMBL15164161 | 0.77 | KDM4E (0.63) | KDM4EPOLA1TAS1R3TAS1R1ADORA1 | |
| SCHEMBL23225351 | 0.75 | KDM4E (0.77) | KDM4EPOLA1TAS1R3TAS1R1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030009027-A1 | C-3' protected monomeric nucleotides and synthesis of oligonucleotides on solid support | LINDEN TECHNOLOGIES, INC., A DELAWARE CORPORATION | 2003-01-09 | — | — | US | disclosed |
| US-6489466-B2 | PRODUCING IMMOBILIZED OLIGONUCLEOTIDES ON A SUBSTRATE BY COVALENTLY ATTACHING A FIRST NUCLEOTIDE OR OLIGONUCLEOTIDE VIA A C-5' OXYGEN OF THE NUCLEOTIDE TO THE SUBSTRATE; C-3'OXYGEN PROTECTED WITH PHOTO- OR CHEMICAL-LABILE GROUPS | LINDEN TECHNOLOGIES, INC. | 2002-12-03 | — | — | US | disclosed |
| US-20010044530-A1 | C-3' protected monomeric nucleotides and synthesis of oligonucleotides on solid support | LINDEN TECHNOLOGIES, INC. | 2001-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010044530-A1 | C-3' protected monomeric nucleotides and synthesis of oligonucleotides on solid support | RNGTT, BCDIN3D, NT5C3B | KDM4E 2813/4885POLA1 305/4885TAS1R3 3876/4885 |
| US-20030009027-A1 | C-3' protected monomeric nucleotides and synthesis of oligonucleotides on solid support | RNGTT, BCDIN3D, NT5C3B | KDM4E 2813/4885POLA1 305/4885TAS1R3 3876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.